Lilly’s decision comes in the context of criticism from US lawmakers of pharmaceutical due to the rising cost of insulin USAbecause in the Presidential Inflation Reduction Act Joe Biden for members of health insurance plans Medicarereports Reuters.

“While we could wait for action by Congress or sanitary system usually apply this standard, we apply it ourselves,” Lilly CEO Dave Ricks told CNN.

In the application, Lilly undertakes to do the following:

• Reduce the price of your branded insulin to $25 per vial: Insulin Lispro for injections 100 units/ml. Effective May 1, 2023, this will be the lowest available list price of insulin for a meal.
• Reduce 70% list price Humalog® (insulin lispro injection) 100 units/mL, which is Lilly’s most commonly prescribed insulin, and Humulin® (human insulin) injectable 100 U/mL2 in 70%, effective Q4 2023.
• Market launch at $92 per container, RezvoglarTM (insulin glargine-aglr), biosimilar and interchangeable basal insulin with Lantus® (insulin glargine), effective April 1, 2020.

“While the current healthcare system provides access to insulin for the majority of people with diabetes, it still does not provide affordable insulin for everyone and this must change,” Dave Ricks said in a statement.

In the United States, according to the American Diabetes Association, 8.4 out of 37 million people with diabetes diabetes they use insulin. A study published in the Annals of Internal Medicine found that up to 1.3 million Americans may have normalized your dose insulin in 2021.

Previously, according to the Insulin Initiative, the price of insulin was over $275 per vial, a 1,200% increase over the past 20 years, according to Reuters.